Waystar Holding Corp. (NASDAQ:WAY) has emerged as one of the best digital health stocks to consider adding to your investment portfolio. Mizuho Securities recently raised its target price for Waystar from $48 to $50 after the company’s strong third-quarter earnings report. The firm reiterated an Outperform rating, citing the increasing demand for Waystar’s revenue cycle management solutions. One of the key factors contributing to the company’s impressive performance was the adoption of AI-driven claims denial tools.
On October 29, 2025, Waystar Holding Corp. released its third-quarter earnings report, showcasing double-digit revenue growth. The company saw steady transaction volume, expanding client adoption, and successful cross-selling with Iodine Software that drove revenue up by 12% to $268.7 million. Adjusted EBITDA remained strong at $112.7 million, with a 42% margin. Cost discipline and scale optimization further boosted profitability, resulting in a net income of $30.6 million. Management expressed confidence in the company’s performance by raising full-year targets, with revenue expected to reach $1.085–$1.093 billion and adjusted EBITDA projected to be $451–$455 million for the year.
Waystar Holding Corp. specializes in healthcare payments and revenue cycle technology, offering cloud-based software solutions for managing claims processing, billing, prior authorizations, and patient financial interactions for hospitals, physician groups, and other healthcare organizations.
While Waystar Holding Corp. presents an appealing investment opportunity, investors may also want to explore other AI stocks with potentially higher upside potential and lower downside risk. For those seeking an undervalued AI stock poised to benefit from current market trends, a free report on the best short-term AI stock is available for consideration.
In conclusion, Waystar Holding Corp. continues to show strength in the digital health sector, with a focus on innovative solutions for healthcare revenue cycle management. Investors looking to diversify their portfolios with exposure to the digital health industry may find Waystar to be a compelling option for consideration.
